Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 13/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | ALDH1A3 | P47895 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5226124 | 0.84 | GRM5 (0.72) | GRM5CLK4CYP1A2CYP3A4ALOX15 | |
| SCHEMBL5100385 | 0.79 | GRM5 (0.65) | GRM5ALDH1A1 | |
| SCHEMBL3923401 | 0.77 | GRM5 (1.00) | GRM5CLK4 | |
| SCHEMBL5201721 | 0.77 | GRM5 (1.00) | GRM5CLK4CYP1A2CYP3A4ALOX15 | |
| SCHEMBL5201644 | 0.76 | GRM5 (0.67) | GRM5CLK4CYP1A2CYP3A4ALOX15 | |
| SCHEMBL5114264 | 0.76 | GRM5 (0.61) | GRM5CLK4CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL3922673 | 0.75 | GRM5 (1.00) | GRM5CLK4CYP1A2CYP3A4ALOX15 | |
| SCHEMBL5100840 | 0.75 | GRM5 (1.00) | GRM5ALDH1A1 | |
| SCHEMBL18411435 | 0.72 | GRM5 (0.62) | GRM5CLK4ALDH1A1 | |
| SCHEMBL18411315 | 0.72 | GRM5 (0.62) | GRM5CLK4ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371767-B2 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | claimed |
| US-20050085514-A1 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-04-21 | — | — | US | claimed |
| EP-1458710-A4 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-04-20 | — | — | EP | claimed |
| EP-1458710-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | claimed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | claimed |
| WO-2003059904-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | claimed |
| US-7371767-B2 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK & CO., INC. (US) | 2008-05-13 | — | — | US | disclosed |
| US-20050085514-A1 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | MERCK SHARP & DOHME CORP. | 2005-04-21 | — | — | US | disclosed |
| EP-1458710-A4 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO INC (US) | 2005-04-20 | — | — | EP | disclosed |
| EP-1458710-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | Merck & Co., Inc. (US) | 2004-09-22 | — | — | EP | disclosed |
| WO-2004030637-A2 | TREATMENT OF OBESITY AND OTHER DISORDERS ASSOCIATED WITH EXCESSIVE FOOD INTAKE | MERCK & CO., INC. (US) | 2004-04-15 | — | — | WO | disclosed |
| WO-2003059904-A1 | HETEROARYL SUBSTITUTED PYRROLE MODULATORS OF METABOTROPIC GLUTAMATE RECEPTOR-5 | MERCK & CO., INC. (US) | 2003-07-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085514-A1 | Heteroaryl substituted pyrrole modulators of metabotropic glutamate receptor-5 | GRM5, GRIK5, GRIN2C | GRM5 1/4885CLK4 1788/4885CYP1A2 2361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.